# Metadata

- ID: 66f26c5f821e116aacb2907c
- Domain: Multi-Document QA
- Subdomain: Financial
- Difficulty: hard
- Length: medium

# Question

Which of the following is a competitive advantage of the multinational pharmaceutical company AbbVie Inc.?

# Choices

- A: Strategic collaborations with other pharmaceutical companies, academic institutions, and research organizations endow AbbVie with robust R&D capabilities, with five new drugs currently in the pipeline submitted for market approval.
- B: AbbVie's business is spread across more than 170 countries worldwide, with particularly impressive growth in developed markets such as the United States, Europe, and Japan.
- C: AbbVie owns a strong portfolio of patent-protected pharmaceutical products, with best-selling drugs such as Humira, Imbruvica, and Venclexta driving the company's revenue growth.
- D: AbbVie continues to leverage external resources to expand its oncology portfolio. On December 6, 2023, the company announced the acquisition of Cerevel Therapeutics, a biopharmaceutical company focused on the treatment of schizophrenia, Parkinson's disease, and mood disorders.

# Answer

A
